HER2 Positive: 152 Real Stories

152 stories match HER2 positive. 135 of them mention chemotherapy.

Cancer Stories

Olivia, who was diagnosed with Stage IV Inflammatory Breast CancerBreast Cancer

Stage IV HER2-Positive Inflammatory Breast Cancer: Olivia's Survivor Story

Patient Info: Olivia Franz, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Bones; distant lymph nodes

As of October 2023, Olivia continued to show no evidence of disease on scans while receiving maintenance trastuzumab and pertuzumab every 3 weeks and zoledronic acid every 3 months for bone health.

MD Anderson
OutcomeCancer-Free / NED
Brian, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV HER2-Positive Colorectal Cancer: Brian's Patient Story

Patient Info: Brian Beck, 50s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

Brian was receiving tucatinib plus trastuzumab on a clinical trial and was working full time 4.5 years after his Stage IV diagnosis.

AACR
OutcomeCare Ongoing
Nikki, who was diagnosed with Stage III Inflammatory Breast CancerBreast Cancer

Stage III HER2-Positive Inflammatory Breast Cancer: Nikki's Patient Story

Patient Info: Nikki, Female | Stage III

Biomarkers: HER2-positive; hormone receptor-positive

After 7 chemotherapy rounds, imaging showed no visible disease, but the team expected possible microscopic cancer. A single mastectomy, radiation and long-term hormone therapy were still planned, so she was not classified as cancer-free.

The Patient Story
OutcomeCare Ongoing / Surgery Planned
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

HER2-positive metastatic lung cancer treated with trastuzumab deruxtecan (Enhertu)

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ERBB2/HER2 copy-number gain of at least 20 copies; TP53 C242fs; CDK12 copy-number gain; tumour mutational burden 3.2 mutations/Mb

Metastatic Site: lungs / multiple pulmonary nodules

Trastuzumab deruxtecan reduced the pulmonary nodules by more than 50% at 3 months and produced a documented response lasting 13.8 months.

PubMed Central
OutcomeResponding Well
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer on hemodialysis: partial response to T-DM1 then no metabolically active disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: Hormone receptor-positive; HER2/neu-positive; E-cadherin-positive; Ki-67 55-60%; luminal B type

As of March 2023, after 12 total cycles of T-DM1 and modified radical mastectomy, PET-CT showed no metabolically active disease, and she continued endocrine therapy and dialysis.

PubMed Central
OutcomeCancer-Free / NED
Lanie, who was diagnosed with Stage II Invasive Ductal CarcinomaBreast Cancer

Stage II HER2-Positive Invasive Ductal Carcinoma: Lanie's Patient Story

Patient Info: Lanie Jones, Female, Under 40 | Stage II

Biomarkers: HER2-positive; Li-Fraumeni syndrome / TP53 mutation; BRCA-negative

As of January 2023, Lanie was living with Li-Fraumeni syndrome after 5 cancer diagnoses and was on lifelong maintenance chemotherapy while advocating for genetic testing and specialized surveillance.

The Patient Story
OutcomeCare Ongoing
Becki, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Becki's Patient Story

Patient Info: Becki, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of 2023, Becki was receiving ongoing treatment for Stage II triple-positive breast cancer after recently completing mastectomy and experiencing chemotherapy-related fatigue, hair loss, and chemo fog.

Our Cancer Stories
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Breast Cancer Treatment Caused Severe Circulation Problems in Her Fingers and Toes

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; ER-negative; PR-negative

The digital ischaemia improved after gemcitabine was stopped, without revascularisation, debridement or amputation, although a small necrotic fingertip area persisted at 3 months. Metastatic breast cancer treatment continued with further systemic lines after progression.

PubMed Central
OutcomeLiving With Cancer / Ongoing Treatment
Feyama, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Feyama's Survivor Story

Patient Info: Feyama Ashby, Female

Biomarkers: HER2-positive

As of September 2022, Feyama had completed chemotherapy, lumpectomy with lymph-node removal, reconstruction, and 6 weeks of VMAT radiation, and was entering close monitoring for 5 years before survivorship clinic follow-up.

MD Anderson
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Cancer in Accessory Breast Tissue Under Both Arms in a Man

Patient Info: Anonymized, Male

Biomarkers: Left tumor: HER2-positive by gene amplification; ER-negative; PR-negative; Ki-67 70%; p53 staining 80%

After surgery removed both accessory-breast cancers, he continued with adjuvant paclitaxel, trastuzumab and radiation.

PubMed Central
OutcomeCare Ongoing
Tamara, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Tamara's Patient Story

Patient Info: Tamara, Female, Under 40

Biomarkers: HER2-positive

As of April 2022, Tamara was 4 years from HER2-positive breast cancer treatment and still in periodic follow-up before reaching the 5-year mark after treatment.

MatchTrial Historias Reales
OutcomeCare Ongoing
María, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HER2-Positive Breast Cancer: María's Survivor Story

Patient Info: María Ángeles, Female | Stage II

Biomarkers: HER2-positive

As of March 2022, María Ángeles was 4 years from diagnosis after completing 14 chemotherapy sessions, mastectomy with immediate reconstruction, 21 radiation sessions, and trastuzumab for Stage II HER2-positive breast cancer.

MatchTrial Historias Reales
OutcomeSurvivorship / Completed Treatment
Loli, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HER2-Positive Breast Cancer: Loli's Patient Story

Patient Info: Loli, Female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Liver

As of March 2022, Loli was living with HER2-positive metastatic breast cancer involving the liver and receiving clinical-trial treatment with chemotherapy every 21 days.

MatchTrial Historias Reales
OutcomeLiving With Cancer
A patient, who was diagnosed with Breast CancerBreast Cancer

Rare HER2-positive mucinous cystadenocarcinoma of the breast

Patient Info: Anonymized, Female, 60s

Biomarkers: HER2-positive; ER-negative; PR-negative

She remained on systemic chemotherapy at the latest documented point, 6 months after starting treatment.

PubMed Central
OutcomeCare Ongoing
Bryan, who was diagnosed with Stage IV Gastric CancerGastric Cancer

Stage IV HER2-Positive Gastric Cancer: Bryan's Patient Story

Patient Info: Bryan Chagolla, Male, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

Bryan had a strong response to trastuzumab deruxtecan in 2021. He died on May 13, 2022, surrounded by loved ones.

AACR
OutcomeIn Memory
Tammy, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage I HER2-Positive Invasive Ductal Carcinoma: Tammy's Patient Story

Patient Info: Tammy, Female | Stage I

Biomarkers: HER2-positive; triple-positive breast cancer

As of September 2021, this story segment described the start of Tammy’s adjuvant treatment plan after HER2-positive, triple-positive Stage I invasive ductal carcinoma was found; no later outcome was stated in this record.

YouTube — Tammy Salamone - The Pink Survivor
OutcomeCare Ongoing
Joy, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Joy's Survivor Story

Patient Info: Joy Albi

Biomarkers: HER2-positive

Joy was in complete remission after the breast tumor was removed and she completed systemic chemotherapy.

Dana-Farber
OutcomeCancer-Free / NED
A patient, who was diagnosed with Small Cell Lung CancerBreast Cancer

Primary small-cell neuroendocrine breast cancer treated with mastectomy

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative; HER2 not overexpressed; Ki-67 90%; synaptophysin-positive; chromogranin A-positive; TTF-1-positive.

Her postoperative recovery was uncomplicated, and she was referred for adjuvant oncology after chemotherapy and radiation were recommended.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

HER2-positive left breast cancer treated with trastuzumab and mastectomy

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2/CerbB2 strongly positive; BRCA1/2 negative for known pathogenic variants; FANCA variant of uncertain significance.

She remained alive, asymptomatic, and disease-free while undergoing annual surveillance after treatment for the left HER2-positive breast cancer.

PubMed Central
OutcomeCancer-Free / NED